# A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence

> **NCT03194542** · PHASE2 · COMPLETED · sponsor: **Celgene** · enrollment: 95 (actual)

## Conditions studied

- Primary Myelofibrosis
- Anemia

## Interventions

- **DRUG:** Luspatercept

## Key facts

- **NCT ID:** NCT03194542
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-15
- **Primary completion:** 2022-07-18
- **Final completion:** 2022-07-18
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2023-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03194542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03194542, "A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03194542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*